188 related articles for article (PubMed ID: 12186633)
1. Cell-surface prion protein interacts with glycosaminoglycans.
Pan T; Wong BS; Liu T; Li R; Petersen RB; Sy MS
Biochem J; 2002 Nov; 368(Pt 1):81-90. PubMed ID: 12186633
[TBL] [Abstract][Full Text] [Related]
2. Heparin binding by murine recombinant prion protein leads to transient aggregation and formation of RNA-resistant species.
Vieira TC; Reynaldo DP; Gomes MP; Almeida MS; Cordeiro Y; Silva JL
J Am Chem Soc; 2011 Jan; 133(2):334-44. PubMed ID: 21142149
[TBL] [Abstract][Full Text] [Related]
3. Ligand binding promotes prion protein aggregation--role of the octapeptide repeats.
Yu S; Yin S; Pham N; Wong P; Kang SC; Petersen RB; Li C; Sy MS
FEBS J; 2008 Nov; 275(22):5564-75. PubMed ID: 18959744
[TBL] [Abstract][Full Text] [Related]
4. Prion proteins with insertion mutations have altered N-terminal conformation and increased ligand binding activity and are more susceptible to oxidative attack.
Yin S; Yu S; Li C; Wong P; Chang B; Xiao F; Kang SC; Yan H; Xiao G; Grassi J; Tien P; Sy MS
J Biol Chem; 2006 Apr; 281(16):10698-705. PubMed ID: 16478730
[TBL] [Abstract][Full Text] [Related]
5. Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges.
González-Iglesias R; Pajares MA; Ocal C; Espinosa JC; Oesch B; Gasset M
J Mol Biol; 2002 May; 319(2):527-40. PubMed ID: 12051926
[TBL] [Abstract][Full Text] [Related]
6. Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans.
Yin S; Pham N; Yu S; Li C; Wong P; Chang B; Kang SC; Biasini E; Tien P; Harris DA; Sy MS
Proc Natl Acad Sci U S A; 2007 May; 104(18):7546-51. PubMed ID: 17456603
[TBL] [Abstract][Full Text] [Related]
7. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.
Hallak LK; Collins PL; Knudson W; Peeples ME
Virology; 2000 Jun; 271(2):264-75. PubMed ID: 10860881
[TBL] [Abstract][Full Text] [Related]
8. Heparinase I-specific disaccharide unit of heparin is a key structure but insufficient for exerting anti-prion activity in prion-infected cells.
Teruya K; Wakao M; Sato M; Hamanaka T; Nishizawa K; Funayama Y; Sakasegawa Y; Suda Y; Doh-ura K
Biochem Biophys Res Commun; 2015 May; 460(4):989-95. PubMed ID: 25839661
[TBL] [Abstract][Full Text] [Related]
9. Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate.
Gabizon R; Meiner Z; Halimi M; Ben-Sasson SA
J Cell Physiol; 1993 Nov; 157(2):319-25. PubMed ID: 7901226
[TBL] [Abstract][Full Text] [Related]
10. Glycosaminoglycan sulfation determines the biochemical properties of prion protein aggregates.
Ellett LJ; Coleman BM; Shambrook MC; Johanssen VA; Collins SJ; Masters CL; Hill AF; Lawson VA
Glycobiology; 2015 Jul; 25(7):745-55. PubMed ID: 25701659
[TBL] [Abstract][Full Text] [Related]
11. Binding of bovine prion protein to heparin: a fluorescence polarization study.
Andrievskaia O; Potetinova Z; Balachandran A; Nielsen K
Arch Biochem Biophys; 2007 Apr; 460(1):10-6. PubMed ID: 17353004
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake.
Wolf H; Graßmann A; Bester R; Hossinger A; Möhl C; Paulsen L; Groschup MH; Schätzl H; Vorberg I
J Virol; 2015 Oct; 89(19):9853-64. PubMed ID: 26202247
[TBL] [Abstract][Full Text] [Related]
13. Prion protein selectively binds copper(II) ions.
Stöckel J; Safar J; Wallace AC; Cohen FE; Prusiner SB
Biochemistry; 1998 May; 37(20):7185-93. PubMed ID: 9585530
[TBL] [Abstract][Full Text] [Related]
14. High-level expression and characterization of a purified 142-residue polypeptide of the prion protein.
Mehlhorn I; Groth D; Stöckel J; Moffat B; Reilly D; Yansura D; Willett WS; Baldwin M; Fletterick R; Cohen FE; Vandlen R; Henner D; Prusiner SB
Biochemistry; 1996 Apr; 35(17):5528-37. PubMed ID: 8611544
[TBL] [Abstract][Full Text] [Related]
15. Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment.
Pérez M; Wandosell F; Colaço C; Avila J
Biochem J; 1998 Oct; 335 ( Pt 2)(Pt 2):369-74. PubMed ID: 9761736
[TBL] [Abstract][Full Text] [Related]
16. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
[TBL] [Abstract][Full Text] [Related]
17. Molecular properties of complexes formed between the prion protein and synthetic peptides.
Kaneko K; Wille H; Mehlhorn I; Zhang H; Ball H; Cohen FE; Baldwin MA; Prusiner SB
J Mol Biol; 1997 Jul; 270(4):574-86. PubMed ID: 9245588
[TBL] [Abstract][Full Text] [Related]
18. Binding of recombinant but not endogenous prion protein to DNA causes DNA internalization and expression in mammalian cells.
Yin S; Fan X; Yu S; Li C; Sy MS
J Biol Chem; 2008 Sep; 283(37):25446-25454. PubMed ID: 18622017
[TBL] [Abstract][Full Text] [Related]
19. Divergent heparin-induced fibrillation pathways of a prion amyloidogenic determinant.
Bazar E; Jelinek R
Chembiochem; 2010 Sep; 11(14):1997-2002. PubMed ID: 20799315
[TBL] [Abstract][Full Text] [Related]
20. Protein interactome analysis of iduronic acid-containing glycosaminoglycans reveals a novel flagellar invasion factor MbhA.
Hsiao FS; Yang SK; Lin JM; Chen YW; Chen CS
J Proteomics; 2019 Sep; 208():103485. PubMed ID: 31421271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
